Adopting a moderate risk posture, health authorities are proceeding with broader clinical integration of semaglutide and tirzepatide, backed by stringent post-marketing surveillance and targeted translational studies. While evidence highlights significant metabolic and cardiovascular benefits, ongoing safety signals necessitate vigilant monitoring for adverse effects like hair shedding and acute pancreatitis. Meanwhile, advancements in nephrology bolster the case for these therapies, but researchers remain skeptical about bridging preclinical successes to real-world clinical outcomes.
Title not available for this citation.
“A total of 60 patients (mean age 61.1 ± 10.8 years, 73% male) were included. At discharge, all received semaglutide...”
Title not available for this citation.
“Body weight decreased by 4.7 ± 1.6 kg...”
Title not available for this citation.
“HbA1c improved from 64.3 ± 18.2 to 49.6 ± 10.4 mmol/mol.”
Title not available for this citation.
“At the second follow-up (278 ± 60 days, n = 39), 97.4% were still on semaglutide.”
Title not available for this citation.
“We report a 59-year-old man with type 2 diabetes,... who developed acute pancreatitis after 2.5 years of weekly semaglutide therapy.”
Title not available for this citation.
“The patient improved with conservative management, and semaglutide was discontinued in favor of linagliptin, with no recurrence of symptoms during three months of follow-up.”
Title not available for this citation.
“Among 152 eligible participants, 70.4% (n = 107) reported hair shedding after GLP-1 RA initiation, which was markedly higher than the 3-7% reported in clinical trials.”
Title not available for this citation.
“Tirzepatide users had the highest prevalence (76.7%), followed by semaglutide (64%) and liraglutide (54.5%).”
Title not available for this citation.
“Hair shedding was significantly associated with female sex (92.5% vs. 75.6% in males, p = 0.009).”
Title not available for this citation.
“Critically, 39.7% of the affected patients cited hair shedding as their reason for discontinuation.”
Title not available for this citation.
“Heart failure with preserved ejection fraction (HFpEF) represents approximately half of all heart failure cases and poses a growing global health challenge driven by an ageing population and an increasing comorbidity burden.”
Title not available for this citation.
“Vitamin deficiency-related TEAEs were reported for 0.99 % and 1.07 % of tirzepatide- and placebo-treated participants, respectively.”
